Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

SRR8518374

· E

e7be761e-b79b-50e3-9ad5-881a5de55cb2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
E
subtype
E

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.360
  • MYC_TARGETS_V1+0.240
  • NOTCH_SIGNALING+0.210
  • WNT_BETA_CATENIN_SIGNALING+0.140
  • PROTEIN_SECRETION+0.100
  • ANGIOGENESIS+0.090
  • MYOGENESIS+0.080
  • HEDGEHOG_SIGNALING+0.040
  • OXIDATIVE_PHOSPHORYLATION+0.040
  • ESTROGEN_RESPONSE_EARLY+0.030

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.600
  • INTERFERON_GAMMA_RESPONSE-0.550
  • IL6_JAK_STAT3_SIGNALING-0.500
  • ALLOGRAFT_REJECTION-0.400
  • PI3K_AKT_MTOR_SIGNALING-0.390
  • IL2_STAT5_SIGNALING-0.370
  • COMPLEMENT-0.350
  • INFLAMMATORY_RESPONSE-0.350
  • TNFA_SIGNALING_VIA_NFKB-0.330
  • MTORC1_SIGNALING-0.310

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1R274
bladder-landscape@3
0.869
2SRR8613748
breast-umap@18
D0.847
3SRR8518202
breast-umap@18
A0.838
44e24bc58-d246-4c96-952a-a18f95d142b2
melanoma-umap@29
0.831
5MBCProject_0297_T1_RNA
breast-umap@18
A0.816
6SRR5088850
melanoma-umap@29
0.813
74ce20929-7d04-4c4b-9e3c-de22d237f254
melanoma-umap@29
0.812
8SRR8613756
breast-umap@18
E0.811
9ERR2208946
melanoma-umap@29
0.807
10ERR2208948
melanoma-umap@29
0.804

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 10 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.360Idelalisib— uncovered
MYC_TARGETS_V10.240Inavolisib— uncovered
NOTCH_SIGNALING0.210Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.140Inavolisib— uncovered
PROTEIN_SECRETION0.100Remibrutinib— uncovered
ANGIOGENESIS0.090Remibrutinib— uncovered
MYOGENESIS0.080Inavolisib— uncovered
HEDGEHOG_SIGNALING0.040Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.040Remibrutinib— uncovered
ESTROGEN_RESPONSE_EARLY0.030Inavolisib— uncovered